[go: up one dir, main page]

MX2018013347A - Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. - Google Patents

Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Info

Publication number
MX2018013347A
MX2018013347A MX2018013347A MX2018013347A MX2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A MX 2018013347 A MX2018013347 A MX 2018013347A
Authority
MX
Mexico
Prior art keywords
hair loss
deuterated
treatment
loss disorders
jak inhibitors
Prior art date
Application number
MX2018013347A
Other languages
English (en)
Other versions
MX388054B (es
Inventor
B Graham Philip
Braman Virginia
T Wagner Amanda
V Cassella James
Uttamsingh Vinita
Von Hehn Jana
E Hamilton Colleen
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018013347(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2018013347A publication Critical patent/MX2018013347A/es
Publication of MX388054B publication Critical patent/MX388054B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para tratar trastornos de pérdida del cabello en un sujeto que se tratan de manera beneficiosa administrando un inhibidor de JAK1 y/o JAK2. El método comprende administrar al sujeto una cantidad en el intervalo de aproximadamente 4 mg a aproximadamente SO mg del Compuesto (I): VER FÓRMULA Compuesto (1) o una sal farmacéuticamente aceptable de este. Esta invención también proporciona composiciones que comprende el Compuesto (I) y el uso de tales composiciones en los métodos descritos.
MX2018013347A 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. MX388054B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (2)

Publication Number Publication Date
MX2018013347A true MX2018013347A (es) 2019-09-02
MX388054B MX388054B (es) 2025-03-19

Family

ID=60203616

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2018013347A MX388054B (es) 2016-05-04 2017-05-04 Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2023002324A MX2023002324A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2021014175A MX2021014175A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002321A MX2023002321A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002323A MX2023002323A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2023002325A MX2023002325A (es) 2016-05-04 2018-10-31 Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.

Country Status (21)

Country Link
US (3) US10561659B2 (es)
EP (2) EP4424367A3 (es)
JP (3) JP7145080B2 (es)
KR (3) KR20250070139A (es)
CN (1) CN109069493A (es)
AU (3) AU2017261286B2 (es)
BR (1) BR112018072339A2 (es)
CA (1) CA3022519A1 (es)
DK (1) DK3452039T3 (es)
ES (1) ES2988629T3 (es)
FI (1) FI3452039T3 (es)
HR (1) HRP20241345T1 (es)
HU (1) HUE068643T2 (es)
LT (1) LT3452039T (es)
MX (6) MX388054B (es)
PL (1) PL3452039T3 (es)
PT (1) PT3452039T (es)
RS (1) RS66006B1 (es)
SI (1) SI3452039T1 (es)
SM (1) SMT202400389T1 (es)
WO (1) WO2017192905A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3452039T (lt) * 2016-05-04 2024-10-25 Sun Pharmaceutical Industries, Inc. Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais
AU2020219797B2 (en) * 2019-02-06 2025-10-16 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched jak inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CA3196551A1 (en) 2020-10-28 2022-05-05 Sun Pharmaceutical Industries, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
AU2022328272A1 (en) * 2021-08-11 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
IL316549A (en) 2022-05-04 2024-12-01 Sun Pharmaceutical Ind Inc Dosing regimens for treatment with dual JAK inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
MXPA03009971A (es) 2001-05-03 2004-02-12 Hoffmann La Roche FORMA DE DOSIFICACIoN FARMACEUTICA DE MESILATO DE NELFINAVIR AMORFO.
EP1809247A1 (en) 2004-09-29 2007-07-25 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
EP3838903B1 (en) 2005-12-13 2023-11-22 Incyte Holdings Corporation Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
KR102027394B1 (ko) * 2010-11-02 2019-10-01 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
HRP20181976T1 (hr) 2012-03-29 2019-01-25 The Trustees Of Columbia University In The City Of New York Postupci za liječenje poremećaja gubitka kose
RS67061B1 (sr) 2012-06-15 2025-08-29 Sun Pharmaceutical Industries Inc Deuterisani derivati ruksolitiniba
CN104507946A (zh) * 2012-07-30 2015-04-08 康塞特医药品有限公司 氘代依鲁替尼
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
US10166183B2 (en) * 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
LT3452039T (lt) 2016-05-04 2024-10-25 Sun Pharmaceutical Industries, Inc. Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais

Also Published As

Publication number Publication date
KR102810262B1 (ko) 2025-05-19
US10561659B2 (en) 2020-02-18
PT3452039T (pt) 2024-10-07
JP7586868B2 (ja) 2024-11-19
EP3452039B1 (en) 2024-07-03
ES2988629T3 (es) 2024-11-21
AU2017261286B2 (en) 2023-03-23
RS66006B1 (sr) 2024-10-31
AU2023201112A1 (en) 2023-03-30
JP2019516684A (ja) 2019-06-20
MX2023002321A (es) 2023-03-22
PL3452039T3 (pl) 2024-11-18
CN109069493A (zh) 2018-12-21
MX2023002324A (es) 2023-03-22
EP3452039A4 (en) 2019-12-25
CA3022519A1 (en) 2017-11-09
DK3452039T3 (da) 2024-10-07
AU2025213576A1 (en) 2025-08-21
MX2023002323A (es) 2023-03-22
JP2022171838A (ja) 2022-11-11
KR20250070139A (ko) 2025-05-20
LT3452039T (lt) 2024-10-25
KR20230086814A (ko) 2023-06-15
EP4424367A2 (en) 2024-09-04
SMT202400389T1 (it) 2024-11-15
MX388054B (es) 2025-03-19
AU2017261286A1 (en) 2018-11-22
KR20190003711A (ko) 2019-01-09
JP2025026895A (ja) 2025-02-26
SI3452039T1 (sl) 2024-12-31
HRP20241345T1 (hr) 2024-12-20
US20240423986A1 (en) 2024-12-26
MX2023002325A (es) 2023-03-22
JP7145080B2 (ja) 2022-09-30
US12076323B2 (en) 2024-09-03
FI3452039T3 (fi) 2024-10-02
BR112018072339A2 (pt) 2019-02-19
EP3452039A1 (en) 2019-03-13
US20200222408A1 (en) 2020-07-16
HUE068643T2 (hu) 2025-01-28
WO2017192905A1 (en) 2017-11-09
EP4424367A3 (en) 2024-11-13
AU2023201112B2 (en) 2025-05-08
MX2021014175A (es) 2022-01-04
US20190160068A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
MX2018013347A (es) Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
EA202190630A1 (ru) Способы комбинированной терапии
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
MX2019007156A (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
MX2024008551A (es) Terapias de combinacion.
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX384721B (es) Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR111233A1 (es) Inhibidores de tyk2, usos y métodos para la producción de los mismos
EA201790088A1 (ru) Ингибиторы syk
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
EA201692267A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
CO2023006808A2 (es) Regímenes para el tratamiento de los trastornos de la pérdida de cabello con inhibidores de jak deuterados
CO2022000266A2 (es) Inhibidores de enzimas
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CO2022008690A2 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
CL2021000660A1 (es) Compuestos quelantes de hierro para tratar condiciones estéticas de la piel
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
UY38133A (es) Nuevos inhibidores de cdk8/19
DOP2025000167A (es) Inhibidores de prmt5–mta
EA201892360A1 (ru) Лечение нарушений, характеризующихся выпадением волос, с помощью дейтерированных ингибиторов jak